Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence

Annals of Intensive Care

Table 1 Cefiderocol clinical breakpoints for interpretation of in vitro susceptibility testing results by Clinical and Laboratory Standards Institute (CLSI) [24], US Food and Drug Administration (FDA) [25], and European Committee on Antimicrobial Susceptibility Testing (EUCAST) [26] for Gram-negative pathogens

	Interpretive criteria according to Minimum inhibitory concentration (µg/mL)
	S^a	I^b	R^c
Enterobacterales
CLSI	≤ 4	8	≥ 16
FDA	≤ 4	8	≥ 16
EUCAST	≤ 2	–	> 2
Pseudomonas aeruginosa
CLSI	≤ 4	8	≥ 16
FDA	≤ 1	2	≥ 4
EUCAST	≤ 2	–	> 2
Acinetobacter baumannii
CLSI	≤ 4	8	≥ 16
FDA	≤ 1	2	≥ 4
EUCAST^d	IE	–	IE
Stenotrophomonas maltophilia
CLSI^e	≤ 1	–	–
FDA^f	–	–	–
EUCAST^d	IE	–	IE

^aS: susceptible for CLSI and FDA; susceptible, standard dosing regimen for EUCAST.
^bI: intermediate for CLSI and FDA; susceptible, increased exposure for EUCAST; EUCAST does not foresee an "I" category for cefiderocol for Enterobacterales or P. aeruginosa.
^cR: resistant.
^dEUCAST has not set clinical breakpoints for cefiderocol for Acinetobacter and S. maltophilia due to insufficient evidence (IE).
^eCLSI does not foresee “I” and “R” categories for S. maltophilia.
^fFDA does not foresee clinical breakpoints for S. maltophilia.